Drugs / DNDI-0690
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03929016 | Apr → Dec 2019 | cutaneous leishmaniasis, visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNDI-0690 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03929016 ↗ |
| Modality | Small molecule | — CHEMBL4069220 ↗ |
| Route | Oral | “After Oral Dosing in Healthy Subjects” NCT03929016 ↗ |